X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-14
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37417,478-   
Low Rs12910,661-   
Sales per share (Unadj.) Rs197.83,147.4-  
Earnings per share (Unadj.) Rs21.2-392.8-  
Cash flow per share (Unadj.) Rs34.7288.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.96,826.5-  
Shares outstanding (eoy) m80.69265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.5 28.5%   
Avg P/E ratio x11.9-35.8 -33.1%  
P/CF ratio (eoy) x7.248.7 14.9%  
Price / Book Value ratio x1.42.1 67.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3063,741,152 0.5%   
No. of employees `0000.821.6 3.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.738,744.6 49.7%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-4,834.9 -42.7%   
INCOME DATA
Net Sales Rs m15,961836,882 1.9%  
Other income Rs m265-2,089 -12.7%   
Total revenues Rs m16,226834,794 1.9%   
Gross profit Rs m4,103107,509 3.8%  
Depreciation Rs m1,091181,216 0.6%   
Interest Rs m94426,397 3.6%   
Profit before tax Rs m2,334-102,192 -2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-7,496 0.0%   
Tax Rs m624-5,254 -11.9%   
Profit after tax Rs m1,711-104,434 -1.6%  
Gross profit margin %25.712.8 200.1%  
Effective tax rate %26.75.1 519.8%   
Net profit margin %10.7-12.5 -85.9%  
BALANCE SHEET DATA
Current assets Rs m11,018440,930 2.5%   
Current liabilities Rs m9,517321,567 3.0%   
Net working cap to sales %9.414.3 65.9%  
Current ratio x1.21.4 84.4%  
Inventory Days Days11058 190.5%  
Debtors Days Days3566 52.6%  
Net fixed assets Rs m16,304102,192 16.0%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,815,167 0.8%   
Long term debt Rs m4,189951,183 0.4%   
Total assets Rs m29,8053,326,604 0.9%  
Interest coverage x3.5-2.9 -120.9%   
Debt to equity ratio x0.30.5 55.1%  
Sales to assets ratio x0.50.3 212.9%   
Return on assets %8.9-2.3 -379.8%  
Return on equity %11.8-5.8 -204.9%  
Return on capital %17.5-3.0 -582.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786143,709 1.9%  
From Investments Rs m-1,529-344,094 0.4%  
From Financial Activity Rs m-941193,331 -0.5%  
Net Cashflow Rs m316-7,054 -4.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.07 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  LUPIN LTD  DR. REDDYS LAB  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS